Research on hypokalemic events based on laboratory test results in hospitalized patients at 199 Hospital, Ministry of Public Security
Tóm tắt: 7
| 
PDF: 8 
##plugins.themes.academic_pro.article.main##
Author
Từ khóa:
Tóm tắt
This study describes the characteristics of hypokalemic events identified through laboratory test results among hospitalized patients at 199 Hospital, Ministry of Public Security and assesses the association between medication use and hypokalemic events. A retrospective cross-sectional study was performed using serum potassium test results and electronic medical records of hospitalized patients from October to December 2024. The results showed that among 78 patients (3.4%) with hypokalemia, 60 patients were assessed as having a relationship between drug use and hypokalemic events. Most patients were female (61.5%), with a mean age of over 70. The majority had endocrine–metabolic, or cardiovascular diseases. More than 80% had at least two comorbidities, and 84.6% experienced only one episode of hypokalemia. The drug classes most frequently associated with hypokalemia were insulin, loop diuretics, and corticosteroids. Regular monitoring of serum potassium levels may facilitate early detection of hypokalemic events and optimize medication use in clinical practice.
Tài liệu tham khảo
-
[1] Ministry of Health, “Guidelines for diagnosis and management in intensive care,” Decision No. 1493/QD-BYT, Hanoi, Vietnam, 2015, pp. 185-193 (in Vietnamese).
[2] Y. Fan et al., “Potassium levels and the risk of all-cause and cardiovascular mortality among patients with cardiovascular diseases: a meta-analysis of cohort studies,” Nutrition Journal, vol. 23, no. 1, p. 88, 2024, doi: 10.1186/s12937-023-00888-z.
[3] B. Song, L. Liu, S. Dong, and S. Wang, “Drug-induced hypokalemia: an analytical study based on real-world drug monitoring data,” Expert Opinion on Drug Safety, vol. 25, no. 5, pp. 847-855, 2025, doi: 10.1080/14740338.2025.2468861.
[4] M. J. Kim, C. Valerio, and G. K. Knobloch, “Potassium Disorders: Hypokalemia and Hyperkalemia,” American Family Physician, vol. 107, no. 1, pp. 59-70, 2023.
[5] National Cancer Institute (NCI), “Common Terminology Criteria for Adverse Events (CTCAE),” United States National Institutes of Health (NIH), v6.0, 2025.
[6] Kidney Disease: Improving Global Outcomes (KDIGO), “KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease,” Kidney Int., vol. 105, no. 4S, Apr. 2024. doi: 10.1016/j.kint.2023.10.018.
[7] World Health Organization, “The WHO-UMC causality assessment system,” Uppsala Monitoring Centre, 2017. [Online]. Available: https://www.who.int/docs/default-source/medicines/pharmacovigilance/whocausality-assessment.pdf [Accessed June 11, 2026].
[8] Norwegian Institute of Public Health (NIPH), “ATC/DDD Index 2026,” Jan. 20, 2026. [Online]. Available: https://atcddd.fhi.no/atc_ddd_index/ [Accessed June 11, 2026].
[9] P. T. T. Hang, “Screening for drug-related dyskalemia events through laboratory test results at the Vietnam National Heart Institute, Bach Mai Hospital,” Bachelor thesis, Hanoi University of Pharmacy, 2019 (in Vietnamese).
[10] H. K. Jensen, M. Brabrand, P. J. Vinholt, J. Hallas, and A. T. Lassen, “Hypokalemia in acute medical patients: risk factors and prognosis,” The American Journal of Medicine, vol. 128, no. 1, pp. 60-67, 2015.
[11] J. Bhargava and S. Viswanathan, “Incidence, Risk Factors and Prognosis of Hypokalaemia in Patients with Normokalaemia at Hospital Admission,” Indian Journal of Endocrinology and Metabolism, vol. 27, no. 6, pp. 537-543, 2024. doi: 10.4103/ijem.ijem_159_23.
[12] L. C. Ring, K. G. Nishide, and E. B. Rangel, “Hypokalemia in Diabetes Mellitus Setting,” Medicina, vol. 58, no. 3, p. 431, 2022, doi: 10.3390/medicina58030431.
[13] M. M. Alosaimi, M. N. Alazwari, A. Alotaibi, and M. E. Alotaibi, “Hypokalemia: Pathophysiology, Diagnosis, and Management,” Journal of Surgery, vol. 10, no. 16, 2025, doi: 10.29011/2575-9760.011511.
##plugins.themes.academic_pro.article.sidebar##
